6640--LAB - CEPHEID MRSA PCR MOLECULAR TESTING

SOL #: 36C24226Q0591Special NoticeSole Source

Overview

Buyer

Veterans Affairs
Veterans Affairs, Department Of
242-NETWORK CONTRACT OFFICE 02 (36C242)
ALBANY, NY, 12208, United States

Place of Performance

Place of performance not available

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

PSC

Laboratory Equipment And Supplies (6640)

Set Aside

No set aside specified

Timeline

1
Posted
May 5, 2026
2
Action Date
May 22, 2026, 4:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Department of Veterans Affairs (DVA) Network Contracting Office NCO2 intends to award a Firm Fixed Price (FFP) sole source contract to Cepheid Inc. for PCR Molecular Diagnostic testing services. This requirement covers the continued use and maintenance of Cepheid GeneXpert and Infinity instruments, along with the supply of necessary reagents, controls, and consumables for various VA Medical Centers in VISN2 South. Capability statements from responsible sources are due by May 22, 2026.

Scope of Work

This opportunity is for the continued provision of Polymerase Chain Reaction (PCR) Molecular Diagnostic testing on a cost-per-reportable/test basis. It includes the use of government-owned and contractor-provided Cepheid GeneXpert and Infinity instruments, their maintenance, and the supply of reagents, controls, consumables, and supplementary items. The comprehensive test menus include MRSA, C.difficile (with/without epidemic strain 027), COVID-19, influenza, RSV, Chlamydia trachomatis/Neisseria gonorrhea, MTB and RIF resistance, strep group A, T.vaginalis, Carbapenemase producing organism identification, MRSA/S.aureus blood culture identification, and MVP identification. Services will be provided to Brooklyn, Castle Point, East Orange, Franklin Delano Roosevelt, James J. Peters, Margaret Cochran, and Northport VA Medical Centers. The use of gray market items is prohibited.

Contract & Timeline

  • Type: Firm Fixed Price (FFP), Sole Source (intended)
  • Intended Contractor: Cepheid Inc.
  • Set-Aside: None (Sole Source)
  • Capability Statement Due: May 22, 2026, 12:00 PM EST
  • Published: May 5, 2026

Evaluation

This is a notice of intent to award a sole source contract, not a request for quotes. Market research, conducted in accordance with FAR Part 10, determined that Cepheid Inc. is the only reasonably capable source due to their ability to provide maintenance and testing supplies for existing DVA-owned equipment and comprehensive test menus. Responsible sources may submit capability statements for government consideration. A determination not to compete this proposed contract based on responses is solely at the Government's discretion.

Additional Notes

This notice satisfies the public posting requirements of FAR 6.301 for justification to limit competition. Veterans Health Administration prohibits the use of gray market items.

People

Points of Contact

Lindsay GoldsmithContracting OfficerPRIMARY

Files

Files

Download

Versions

Version 1Viewing
Special Notice
Posted: May 5, 2026
6640--LAB - CEPHEID MRSA PCR MOLECULAR TESTING | GovScope